Glenmark Pharma Launches Calcium Gluconate Injection in US Market Worth $69.9 Million
Glenmark Pharmaceuticals Inc., USA has introduced Calcium Gluconate Injection USP in multiple dosage presentations for the United States market. This launch aims to strengthen the company's presence in the U.S. hospital sector by providing bioequivalent therapeutic alternatives to existing critical care medications.
Biocon Ltd Launches Yesafili Biosimilar in US Market to Address USD 5.89 Billion Opportunity
Biocon Limited has initiated the commercial launch of Yesafili, its interchangeable biosimilar to Eylea, in the United States. The launch addresses a multi-billion dollar market opportunity in ophthalmology, providing a new treatment option for millions of Americans suffering from vision-threatening conditions.
Shilpa Medicare Subsidiary Commissions Integrated ADC GMP Facility in Dharwad
Shilpa Biologicals Private Ltd, a subsidiary of Shilpa Medicare, has commissioned an integrated Antibody-Drug Conjugate (ADC) GMP manufacturing facility in Dharwad. This advanced unit enables the company to offer end-to-end development and production of complex oncology drug substances for the global pharmaceutical market.